Top

Published in:

01-04-2014 | Meta- Analysis

The association of SCGB3A2 polymorphisms with the risk of Graves’ disease: a meta-analysis

Authors: Liqiong Xue, Bing Han, Chunming Pan, Huaidong Song

Published in: Endocrine | Issue 3/2014

Abstract

The aim of this study is to assess the association of the SCGB3A2 −112G>A promoter polymorphism with Graves’ disease(GD) using a meta-analysis. Relevant studies were identified using PubMed and EMBASE electronic databases. A meta-analysis of relevant studies was performed. This meta-analysis included four case–control studies, containing 6,913 GD cases (Caucasian 3904, Han 3009) and 7,185 controls(Caucasian 4155, Han 3030). The combined results showed a significant difference in genotype distribution (−112A/G) between GD and control populations (A vs. G P = 1.53 × 10⁻⁷; GG vs. AA+AG P = 6.78 × 10⁻⁹). Meta-analysis was performed using a fixed-effects model. Under the dominant model (GG/AA + GA), the AA and GA genotypes were significantly associated with GD (pooled OR = 1.24, 95 % CI 1.12–1.37). When the two European studies are combined, the AA and GA genotypes were also significantly associated with GD (pooled OR = 1.29, 95 % CI 1.20–1.39). This meta-analysis suggests that SCGB3A2 polymorphism at positions −112G>A was associated with GD both in Chinese and Caucasian population.

M.J. Simmonds, J.M. Howson, J.M. Heward, H.J. Cordell, H. Foxall, J. Carr-Smith, S.M. Gibson, N. Walker, Y. Tomer, J.A. Franklyn, J.A. Todd, S.C. Gough, Regression mapping of association between the human leukocyte antigen region and Graves’ disease. Am. J. Hum. Genet. 76, 157–163 (2005)PubMedCentralPubMedCrossRef

H. Ueda, J.M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D.B. Rainbow, K.M. Hunter, A.N. Smith, G. Di Genova, M.H. Herr, I. Dahlman, F. Payne, D. Smyth, C. Lowe, R.C. Twells, S. Howlett, B. Healy, S. Nutland, H.E. Rance, V. Everett, L.J. Smink, A.C. Lam, H.J. Cordell, N.M. Walker, C. Bordin, J. Hulme, C. Motzo, F. Cucca, J.F. Hess, M.L. Metzker, J. Rogers, S. Gregory, A. Allahabadia, R. Nithiyananthan, E. Tuomilehto-Wolf, J. Tuomilehto, P. Bingley, K.M. Gillespie, D.E. Undlien, K.S. Rønningen, C. Guja, C. Ionescu-Tîrgovişte, D.A. Savage, A.P. Maxwell, D.J. Carson, C.C. Patterson, J.A. Franklyn, D.G. Clayton, L.B. Peterson, L.S. Wicker, J.A. Todd, S.C. Gough, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506–511 (2003)PubMedCrossRef

Y. Tomer, E. Concepcion, D.A. Greenberg, A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves’ disease. Thyroid 12, 1129–1135 (2002)PubMedCrossRef

M.R. Velaga, V. Wilson, C.E. Jennings, C.J. Owen, S. Herington, P.T. Donaldson, S.G. Ball, R.A. James, R. Quinton, P. Perros, S.H. Pearce, The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ disease. J. Clin. Endocrinol. Metab. 89, 5862–5865 (2004)PubMedCrossRef

H. Hiratani, D.W. Bowden, S. Ikegami, S. Shirasawa, A. Shimizu, Y. Iwatani, T. Akamizu, Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves’ disease. J. Clin. Endocrinol. Metab. 90, 2898–2903 (2005)PubMedCrossRef

Y. Jin, W. Teng, S. Ben, X. Xiong, J. Zhang, S. Xu, Y.Y. Shugart, L. Jin, J. Chen, W. Huang, Genome-wide scan of Graves’ disease evidence for linkage on chromosome 5q31 in Chinese pedigrees. J. Clin. Endocrinol. Metab. 88, 1798–1803 (2003)PubMedCrossRef

K. Sakai, S. Shirasawa, N. Ishikawa, K. Ito, H. Tamai, K. Kuma, T. Akamizu, M. Tanimura, K. Furugaki, K. Yamamoto, T. Sasazuki, Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto’s thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. Hum. Mol. Genet. 10, 1379–1386 (2001)PubMedCrossRef

X. Chu, Y. Dong, M. Shen, L. Sun, C. Dong, Y. Wang, B. Wang, K. Zhang, Q. Hua, S. Xu, W. Huang, Polymorphisms in the ADRB2 gene and Graves disease: a case-control study and a meta-analysis of available evidence. BMC Med. Genet. 10, 26 (2009)PubMedCentralPubMedCrossRef

Y. Ikeda, W. Yoshida, T. Noguchi, K. Asaba, T. Nishioka, T. Takao, K. Hashimoto, Lack of association between IL-12B gene polymorphism and autoimmune thyroid disease in Japanese patients. Endocr. J. 51, 609–613 (2004)PubMedCrossRef

10.

Y. Hiromatsu, T. Fukutani, M. Ichimura, T. Mukai, H. Kaku, I. Miyake, K. Yamada, Interleukin-12B gene polymorphism does not confer susceptibility to Graves’ ophthalmopathy in Japanese population. Endocr. J. 53, 753–759 (2006)PubMedCrossRef

11.

Y. Yang, S. Lingling, J. Ying, L. Yushu, S. Zhongyan, H. Wei, T. Weiping, Association study between the IL4, IL13, IRF1 and UGRP1 genes in chromosomal 5q31 region and Chinese Graves’ disease. J. Hum. Genet. 50, 574–582 (2005)PubMedCrossRef

12.

M.J. Simmonds, J.M. Heward, J.A. Franklyn, S.C. Gough, IL-13 and chromosome 5q31-q33: problems of identifying association within regions of linkage to Graves’ disease. Clin. Endocrinol. (Oxf) 63, 695–697 (2005)CrossRef

13.

Y. Hiromatsu, T. Fukutani, M. Ichimura, T. Mukai, H. Kaku, H. Nakayama, I. Miyake, S. Shoji, Y. Koda, T. Bednarczuk, Interleukin-13 gene polymorphisms confer the susceptibility of Japanese populations to Graves’ disease. J. Clin. Endocrinol. Metab. 90, 296–301 (2005)PubMedCrossRef

14.

T. Niimi, M. Munakata, C.L. Keck-Waggoner, N.C. Popescu, R.C. Levitt, M. Hisada, S. Kimura, A polymorphism in the human UGRP1 gene promoter that regulates transcription is associated with an increased risk of asthma. Am. J. Hum. Genet. 70, 718–725 (2002)PubMedCentralPubMedCrossRef

15.

Z. Jian, J. Nakayama, E. Noguchi, M. Shibasaki, T. Arinami, No evidence for association between the −112G/A polymorphism of UGRP1 and childhood atopic asthma. Clin. Exp. Allergy 33, 902–904 (2003)PubMedCrossRef

16.

J. Batra, P.V. Niphadkar, S.K. Sharma, B. Ghosh, Uteroglobin-related protein 1 (UGRP1) gene polymorphisms and atopic asthma in the Indian population. Int. Arch. Allergy Immunol. 136, 1–6 (2005)PubMedCrossRef

17.

A. Heinzmann, H. Dietrich, K.A. Deichmann, Association of uteroglobulinrelated protein 1 with bronchial asthma. Int. Arch. Allergy Immunol. 131, 291–295 (2003)PubMedCrossRef

18.

H.D. Song, J. Liang, J.Y. Shi, S.X. Zhao, Z. Liu, J.J. Zhao, Y.D. Peng, G.Q. Gao, J. Tao, C.M. Pan, L. Shao, F. Cheng, Y. Wang, G.Y. Yuan, C. Xu, B. Han, W. Huang, X. Chu, Y. Chen, Y. Sheng, R.Y. Li, Q. Su, L. Gao, W.P. Jia, L. Jin, M.D. Chen, S.J. Chen, Z. Chen, J.L. Chen, Functional SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves’ disease. Hum. Mol. Genet. 18, 1156–1170 (2009)PubMedCrossRef

19.

M.J. Simmonds, K. Yesmin, P.R. Newby, O.J. Brand, J.A. Franklyn, S.C. Gough, Confirmation of association of chromosome 5q31-33 with United Kingdom Caucasian Graves’ disease. Thyroid 20, 413–417 (2010)PubMedCrossRef

20.

D.A. Chistiakov, N.V. Voronova, R.I. Turakulov, K.V. Savost’anov, The −112G>A polymorphism of the secretoglobin 3A2 (SCGB3A2) gene encoding uteroglobin-related protein 1 (UGRP1) increases risk for the development of Graves’ disease in subsets of patients with elevated levels of immunoglobulin E. J. Appl. Genet. 52, 201–207 (2011)PubMedCrossRef

21.

R. DerSimonian, N. Laird, Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188 (1986)PubMedCrossRef

22.

N. Liu, X. Li, C. Liu, Y. Zhao, B. Cui, G. Ning, The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves’ disease in a case-control study and meta-analysis. Hum. Immunol. 71, 397–401 (2010)PubMedCrossRef

23.

M. Egger, G. Davey Smith, M. Schneider, C. Minder, Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997)PubMedCentralPubMedCrossRef

24.

N. Liu, H. Lu, F. Tao, T. Guo, C. Liu, B. Cui, G. Ning, An association of interleukin-10 gene polymorphisms with Graves’ disease in two Chinese populations. Endocrine 40, 90–94 (2011)PubMedCrossRef

25.

M. Feng, H. Li, S.F. Chen, W.F. Li, F.B. Zhang, Polymorphisms in the vitamin D receptor gene and risk of autoimmune thyroid diseases: a meta-analysis. Endocrine 43, 318–326 (2013)PubMedCrossRef

26.

J. Yang, Q. Qin, N. Yan, Y.F. Zhu, C. Li, X.J. Yang, X. Wang, M. Pandey, P. Hou, J.A. Zhang, CD40 C/T(-1) and CTLA-4 A/G(49) SNPs are associated with autoimmune thyroid diseases in the Chinese population. Endocrine 41, 111–115 (2012)PubMedCrossRef

27.

A.K. Andiappan, W.S. Yeo, P.N. Parate, R. Anantharaman, B.K. Suri, Y. de Wang, F.T. Chew, Variation in uteroglobin-related protein 1 (UGRP1) gene is associated with allergic rhinitis in Singapore Chinese. BMC Med. Genet. 12, 39 (2011)PubMedCentralPubMedCrossRef

28.

Y.H. Lee, S.J. Choi, J.D. Ji, G.G. Song, The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis. Mol. Biol. Rep. 39, 3103–3108 (2012)PubMedCrossRef

29.

Y.H. Lee, S.C. Bae, S.J. Choi, J.D. Ji, G.G. Song, The association between the PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis update. Mol. Biol. Rep. 39, 3453–3460 (2012)PubMedCrossRef

30.

D. Zhebrun, Y. Kudryashova, A. Babenko, A. Maslyansky, N. Kunitskaya, D. Popcova, A. Klushina, E. Grineva, A. Kostareva, E. Shlyakhto, Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves’ disease but not with rheumatoid arthritis in Russian population. Aging (Albany NY) 3, 368–373 (2011)

31.

I. Santin, A. Castellanos-Rubio, A.M. Aransay, L. Castaño, J.C. Vitoria, J.R. Bilbao, The functional R620W variant of the PTPN22 gene is associated with celiac disease. Tissue Antigens 71, 247–249 (2008)PubMedCrossRef

32.

W.W. Lea, Y.H. Lee, The association between the PTPN22 C1858T polymorphism and systemic lupus erythematosus: a meta-analysis update. Lupus 20, 51–57 (2011)PubMedCrossRef

Title: The association of SCGB3A2 polymorphisms with the risk of Graves’ disease: a meta-analysis
Authors: Liqiong Xue
Bing Han
Chunming Pan
Huaidong Song
Publication date: 01-04-2014
Publisher: Springer US
Published in: Endocrine / Issue 3/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-013-0021-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

The exon 3 polymorphism of the growth hormone receptor is a severity-related factor for osteoporosis

Circulating chemerin decreases in response to a combined strength and endurance training

Lymphocytes and immunoglobulin patterns across the threshold of severe obesity

A very rare bilateral adrenal tumor

Lymph node metastasis from undiagnosed occult papillary thyroid cancer

Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials